A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment
Latest Information Update: 04 Dec 2023
At a glance
- Drugs ABBV-154 (Primary) ; Glucocorticoids (Primary)
- Indications Polymyalgia rheumatica
- Focus Therapeutic Use
- Acronyms AIM-PMR
- Sponsors AbbVie; AbbVie Germany
- 27 Aug 2023 This trial has been completed in Austria (Date of the global end of the trial: 24-Jul-2023), according to the European Clinical Trials Database record.
- 03 Aug 2023 Status changed from active, no longer recruiting to discontinued as per business decision.
- 10 Jun 2023 This trial has been discontinued in Spain, according to European Clinical Trials Database record.